Business OpportunityUpdated on 12 October 2025
Developing a new therapy for the treatment of diabetes mellitus
Entrepreneur at ACCIÓ
Barcelona, Spain
About
Engineered Regulatory T-cells to express specific receptors to modulate and restore the immune balance. Experimental validation already done, including preclinical studies and prototype testing. Looking for testing in a realistic environment, clinical trials, and final manufacturing/submission processes.
Stage
- TRL 6
Topic
- Diseases of the blood and immune disorders
- Endocrine/nutritional/metabolic diseases
Sector
- ATMPs
Type
- Co-development
- Regulatory expert
- Consortium partners
Organisation
Similar opportunities
Business Opportunity
- TRL 6
- TRL 7
- TRL 8
- Health data
- Rare diseases
- Research collaboration
- Congenital or chromosomal abnormalities
- Diseases of the blood and immune disorders
Jacques Riviere
Pediatric immunologist, researcher at Vall d'Hebron Research Institute (VHIR)
Barcelona, Spain
Business Opportunity
AI-powered Healthcare with therapeutic red blood cells
- AI
- TRL 6
- ATMPs
- Health data
- Diagnostics
- Rare diseases
- Rare diseases
- Co-development
- Clinical validation
- Regenerative medicine
- Endocrine/nutritional/metabolic diseases
- Diseases of the nervous system / neurology
- Mental and behavioural disorders / psychiatry /psychology
Denis Demarais
Founder and CEO at Rius Medical
Waldachtal, Germany
Business Opportunity
Preclinical Platform for ATMP Evaluation with Patient-Derived Microtumours (PDMs)
- AI
- TRL 6
- ATMPs
- Genomics
- Oncology
- Proteomics
- Health data
- Diagnostics
- Bioinformatics
- Co-development
- Regulatory expert
- Consortium partners
- Research collaboration
- Neoplasms/cancer/oncology
Martin Kriebel
Group Leader (dep.) Cellular & Molecular Biology at NMI Natural and Medical Sciences Institute
Reutlingen, Germany